Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis

Maako Ide, Kentaro Tanaka, Shunya Sunami, Tatsuma Asoh, Takashige Maeyama, Nobuko Tsuruta, Yoichi Nakanishi, Isamu Okamoto

研究成果: Contribution to journalArticle

7 引用 (Scopus)

抜粋

The efficacy and safety of immune-checkpoint inhibitors in non-small cell lung cancer patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Herein, we describe the case of a 62-year-old man with multiple pleural tumors and carcinomatous pleurisy. High-resolution computed tomography indicated usual interstitial pneumonia, and a respiratory function test revealed a restrictive disorder and decreased diffusion capacity. He was diagnosed with lung adenocarcinoma and IPF. After failure of initial chemotherapy, he was treated with nivolumab and achieved a complete response without any sign of exacerbation of IPF. The response to nivolumab has persisted for > 1 year. This is the first report of a non-small cell lung cancer patient with IPF who has been treated with immune-checkpoint inhibitors for such a long period and achieved a sustained response.

元の言語英語
ページ(範囲)1519-1521
ページ数3
ジャーナルThoracic Cancer
9
発行部数11
DOI
出版物ステータス出版済み - 11 2018

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

フィンガープリント Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用